Gardasil Anal Cancer Indication To Face FDA Advisory Committee Scrutiny
This article was originally published in The Pink Sheet Daily
Executive Summary
Supplemental application filed earlier this year is part of Merck's strategy to broaden use of the HPV vaccine, although its bid to expand the label to women ages 27-45 has thus far been blocked by the agency.
You may also be interested in...
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
A Center for Biologics Evaluation and Research clinical reviewer sees no problem with using an anal dysplasia endpoint, or extrapolating male data to females, to support approval of Merck’s human papillomavirus vaccine Gardasil for prevention of anal cancer.
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
A Center for Biologics Evaluation and Research clinical reviewer sees no problem with using an anal dysplasia endpoint, or extrapolating male data to females, to support approval of Merck’s human papillomavirus vaccine Gardasil for prevention of anal cancer.
Gardasil Anal Cancer Indication: CBER Has No Concerns, But What Will ACIP Think?
Nov. 17 session is product's third before an FDA advisory committee, but review by CDC's immunization practices panel may be key for utilization and reimbursement.